Fundraising Fox
/Companies
Sign in

Palisade BIO

Carlsbad, US · Founded 2005 · 25 employees on LinkedIn · 1 known investors

Find your way into Palisade BIO

Sign up to see every warm intro you have to Palisade BIO

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Palisade BIO team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Palisade Bio develops a PDE4 prodrug platform for treating immune, inflammatory, and fibrotic diseases, with improved pharmacokinetics and tolerability compared to traditional PDE4 inhibitors. The company's lead candidate is designed for once-daily dosing with reduced gastrointestinal side effects.

BiotechMedical Devices

Founders & leadership

Palisade BIO was founded in 2005 by I. Richard Garr and Karl Johe.

IR
I. Richard GarrCo-founder
KJ
Karl JoheCo-founder
RMRobert McRae
Robert McRaeChief Operating Officer2023–2023
HS
Herbert SladeExecutive
JF
J.D. FinleyExecutive
JF
JD FinleyChief Executive Officer
MJMitch Jones
Mitch JonesPresident & Chief Medical OfficerHe brings over 18 years of biotechnology and clinical development experience, with expertise in oral therapies for inflammatory and fibrotic diseases, gut tissue immunology, and advancing programs from early-stage to late-stage clinical trials.

Board

SW
Stanley WestreichBoard director
RT
Robert TrenschelBoard director
JN
James NealBoard director
BW
Binxian WeiBoard director
DW
Donald WilliamsBoard director

Investors · 1

Reported raises · per SEC filings

Form D private placements

$54M disclosed across 10 rounds · 2014–2024

▶$4MraisedMay 2024 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Binxian WeiDirector
  • J.D. FinleyExecutive Officer, Director
  • Margery FischbeinDirector
  • Mitchell JonesExecutive Officer
  • Donald WilliamsDirector
Offering amount
$4M
Amount sold
$4M
Sales commissions
$310K
Placement agents
Ladenburg Thalmann & Co. Inc.
First sale
May 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.5MraisedFeb 2024 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mary Ann GrayDirector
  • Donald WilliamsDirector
  • J.D. FinleyExecutive Officer, Director
  • Binxian WeiDirector
  • Mitchell JonesExecutive Officer
Offering amount
$2.5M
Amount sold
$2.5M
Sales commissions
$194K
Placement agents
Ladenburg Thalmann & Co. Inc.
First sale
Feb 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4MraisedApr 2023 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert McRaeExecutive Officer
  • Robert TrenschelDirector
  • James NealDirector
  • Binxian WeiDirector
  • Donald WilliamsDirector
  • Herbert SladeExecutive Officer
  • J.D. FinleyExecutive Officer, Director
  • Stephanie DiazDirector
  • Cristina CsimmaDirector
  • Mary Ann GrayDirector
Offering amount
$4M
Amount sold
$4M
Sales commissions
$310.3K
Placement agents
Ladenburg Thalmann & Co. Inc.
First sale
Apr 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.5MraisedJan 2023 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mary Ann GrayDirector
  • Robert TrenschelDirector
  • Cristina CsimmaDirector
  • James NealDirector
  • Donald WilliamsDirector
  • Stephanie DiazDirector
  • Binxian WeiDirector
  • J.D. FinleyExecutive Officer
Offering amount
$2.5M
Amount sold
$2.5M
Sales commissions
$193.8K
Placement agents
Ladenburg Thalmann & Co. Inc.
First sale
Jan 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.4MraisedMay 2022 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • JD FinleyExecutive Officer
  • Binxian WeiDirector
  • Mary Ann GrayDirector
  • Stephanie C DiazDirector
  • Donald WilliamsDirector
  • James R NealDirector
  • Cristina CsimmaDirector
  • Thomas HallamExecutive Officer, Director
  • Robert TrenschelDirector
Offering amount
$2.4M
Amount sold
$2.4M
Sales commissions
$310.9K
Placement agents
Ladenburg Thalmann & Co. Inc.
First sale
May 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7.6MraisedJan 2020 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Binxian WeiDirector
  • Kenneth CarterExecutive Officer, Director
  • David MazzoDirector
  • Sandford SmithDirector
  • Scott OgilvieDirector
  • Mary Ann GrayDirector
  • Cristina CsimmaDirector
Offering amount
$7.6M
Amount sold
$7.6M
Sales commissions
$604.4K
Placement agents
H.C. Wainwright & Co. LLC
First sale
Jan 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$42KraisedMay 2017 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Scott OgilvieDirector
  • Sandford SmithDirector
  • Stanley WestreichDirector
  • Richard DalyExecutive Officer, Director
  • William OldakerDirector
Offering amount
$42K
Amount sold
$42K
Minimum investment
$12K
First sale
May 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$20MraisedDec 2016 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Stanley WestreichDirector
  • William OldakerDirector
  • Richard DalyExecutive Officer, Director
  • Sandford SmithDirector
  • Catherine SohnDirector
  • Jonathan Lloyd JonesExecutive Officer
  • Scott OgilvieDirector
Offering amount
$20M
Amount sold
$20M
Minimum investment
$20M
First sale
Dec 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Palisade BIO do?
Palisade Bio develops a PDE4 prodrug platform for treating immune, inflammatory, and fibrotic diseases, with improved pharmacokinetics and tolerability compared to traditional PDE4 inhibitors. The company's lead candidate is designed for once-daily dosing with reduced gastrointestinal side effects.
Who founded Palisade BIO?
Palisade BIO was founded by I. Richard Garr, Karl Johe in 2005.
Who are Palisade BIO's investors?
Palisade BIO's investors include Altium Capital.
How much funding has Palisade BIO raised?
Palisade BIO has disclosed $54M raised across 10 rounds.
Where is Palisade BIO headquartered?
Palisade BIO is headquartered in Carlsbad, US.